Gene and Cell Therapy · global
Helping Children with a Rare Disease Leave Protective Environments: Wiskott–Aldrich Gene Therapy Shows Years of Benefit
Long-term data from 27 patients show sustained reductions in severe infections and bleeding after a single infusion of genetically modified autologous hematopoietic stem cells. Results from up to 13 years of follow-up also provide firmer evidence on whether the benefits can last.
For patients with Wiskott–Aldrich syndrome, attending school, playing sports, and even leaving a strictly protective living environment can carry the threat of infection and bleeding. A study involving 27 patients now shows that adding a functional gene to patients’ own hematopoietic stem cells and infusing them back into the body can deliver improvements that last for years and gradually translate into changes in daily life.
The study by Francesca Ferrua and colleagues, published in the September 2026 issue of The New England Journal of Medicine, combines two prospective, open-label clinical studies and an expanded access program. After a single infusion of etuvetidigene autotemcel (etu-cel), overall survival was 96% at both one and five years, with sustained reductions in severe infections and moderate-to-severe bleeding. Vita-Salute San Raffaele University reported a median follow-up of 5.7 years, with some patients followed for 13 years.
This rare X-linked disease is caused by variants in the WAS gene and primarily affects males. The WAS gene produces the WASP protein, which is involved in cytoskeletal function; impaired function damages both the immune system and platelets, causing recurrent infections, bleeding, eczema, and autoimmune complications. Immunoglobulin, anti-infective drugs, and platelet transfusions can address some of these problems but cannot change the disease’s genetic cause.
Etu-cel involves collecting patients’ hematopoietic stem cells, using a lentiviral vector to introduce a functional WAS gene, and then infusing the cells back after reduced-intensity conditioning chemotherapy. This supplies the cells with a working copy of the gene, enabling subsequently generated blood and immune cells to express the WASP protein. Using autologous cells also removes the need to find a matched donor; by comparison, allogeneic hematopoietic stem cell transplantation carries risks including graft-versus-host disease.
The benefits extend beyond records of infections and bleeding. According to the university, three years after treatment, none of the patients still needed to live in a protective environment, about 80% could attend school, and about half could participate in sports. By the last follow-up, all patients had stopped immunoglobulin replacement therapy. These changes in daily life capture aspects of the treatment’s significance that survival rates alone cannot fully convey.
Safety still needs to be understood in the context of the entire treatment process. Citing study data, Medical Xpress reported that the most common adverse events of grade 3 or higher were central venous catheter-related infections, and no cancer-causing effects resulting from vector insertion into the genome have been observed to date. The research team did not attribute the observed adverse events to the gene therapy product itself, but this does not mean that cell collection, conditioning chemotherapy, and infusion are without risk, nor does it rule out problems that may emerge later.
This study provides years of follow-up evidence that is rare in treatments for rare diseases. However, its size of 27 patients, open-label design, and combination of different studies and an access program all limit its ability to compare efficacy; it is not a randomized trial directly comparing gene therapy with allogeneic transplantation. For patients and their families, the results support a treatment approach that may continue to reduce the burden of disease, while lifelong efficacy and rare long-term risks still require more time to confirm.